Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.
Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to ...
LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab ... They said this could be a factor in the low take-up of the highest dose. Novo has said it will start a new ...
Novo Nordisk (NVO) ended the recent trading session ... Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.